Literature DB >> 16752168

The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study.

I Köster1, L von Ferber, P Ihle, I Schubert, H Hauner.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to identify the health care costs of diabetic patients in Germany in 2001, focusing on the influence of age, sex, and type of treatment. SUBJECTS AND METHODS: Annual direct costs of medical care and indirect costs of inability to work and early retirement in diabetic subjects were compared with costs of age- and sex-matched non-diabetic control subjects. The analysis was based on routine health care data from a random sample (18.75%) taken from a database of 1.9 million insured persons. Incremental differences in medical and national expenditure between subjects with and without diabetes were calculated.
RESULTS: Annual direct mean costs per diabetic patient were 5,262 Euro, and indirect costs were 5,019 Euro. In the control group, mean direct and indirect costs were 2,755 Euro and 3,691 Euro, respectively. Analysis of cost components revealed that the high costs associated with the care of diabetic patients could be largely attributed to inpatient care and overall medication costs. Hypoglycaemic drugs amounted to only one-quarter of the medication costs. The total health care costs were correlated with the type of treatment. Direct excess costs increased with increasing age in insulin-treated patients, but were unaffected by age in patients receiving other types of treatment. CONCLUSIONS/
INTERPRETATION: The Costs of Diabetes Mellitus (CoDiM) study is the first comprehensive study to provide estimates of costs associated with diabetes care in Germany. Direct costs of diabetic patients account for 14.2% of total health care costs, which includes the proportion that specifically accounts for diabetes-related costs (6.8%).

Entities:  

Mesh:

Year:  2006        PMID: 16752168     DOI: 10.1007/s00125-006-0277-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle-aged incidence cohorts in Sweden.

Authors:  P M Jonsson; L A Marké; L Nyström; S Wall; J Ostman
Journal:  Diabetes Res Clin Pract       Date:  2000-09       Impact factor: 5.602

2.  Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus.

Authors:  J B Brown; G A Nichols; H S Glauber; A W Bakst; M Schaeffer; C C Kelleher
Journal:  Am J Health Syst Pharm       Date:  2001-01-15       Impact factor: 2.637

Review 3.  [Health economics analysis of diabetes is necessary. It facilitates decision-making and international comparison].

Authors:  F Henriksson; C D Agardh; C Berne; J Bolinder; B Jönsson
Journal:  Lakartidningen       Date:  1999-09-15

4.  Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association.

Authors: 
Journal:  Diabetes Care       Date:  1998-02       Impact factor: 19.112

5.  Productivity and medical costs of diabetes in a large employer population.

Authors:  Scott Ramsey; Kent H Summers; Stephanie A Leong; Howard G Birnbaum; Jason E Kemner; Paul Greenberg
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

6.  [Prevalence of diabetes mellitus in Germany 1998-2001. Secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse].

Authors:  H Hauner; I Köster; L von Ferber
Journal:  Dtsch Med Wochenschr       Date:  2003-12-12       Impact factor: 0.628

7.  The direct medical cost of type 2 diabetes.

Authors:  Michael Brandle; Honghong Zhou; Barbara R K Smith; Deanna Marriott; Ray Burke; Bahman P Tabaei; Morton B Brown; William H Herman
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

8.  Health care expenditures for people with diabetes mellitus, 1992.

Authors:  R J Rubin; W M Altman; D N Mendelson
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

9.  [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study].

Authors:  Andreas Liebl; Andrea Spannheimer; Ursula Reitberger; Anita Görtz
Journal:  Med Klin (Munich)       Date:  2002-12-15

Review 10.  Cost-of-illness studies in diabetes mellitus.

Authors:  Lorraine Ettaro; Thomas J Songer; Ping Zhang; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more
  55 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

2.  Estimation of disease incidence in claims data dependent on the length of follow-up: a methodological approach.

Authors:  Sascha Abbas; Peter Ihle; Ingrid Köster; Ingrid Schubert
Journal:  Health Serv Res       Date:  2012-04       Impact factor: 3.402

3.  [Resource management: ICF-oriented exercise programs for patients with diabetes mellitus type 2. Chronic illnesses and biopsychosocial status].

Authors:  K Pfeifer; G Huber; A Baldus; D Pöthig; K Schüle
Journal:  Z Gerontol Geriatr       Date:  2012-02       Impact factor: 1.281

4.  The economic burden of diabetic retinopathy in Germany in 2002.

Authors:  Michael Happich; Ursula Reitberger; Lusine Breitscheidel; Michael Ulbig; Jessamy Watkins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-04       Impact factor: 3.117

5.  Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program.

Authors:  Tae Ho Kim; Ki Hong Chun; Hae Jin Kim; Seung Jin Han; Dae Jung Kim; Jiyeong Kwak; Young Seol Kim; Jeong Taek Woo; Yongsoo Park; Moonsuk Nam; Sei Hyun Baik; Kyu Jeung Ahn; Kwan Woo Lee
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

Review 6.  Advancing Measurement of Diabetes at the Population Level.

Authors:  Mohammed K Ali; Karen R Siegel; Michael Laxy; Edward W Gregg
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

7.  [Costs involved in the early and late phases of diabetes mellitus].

Authors:  A Liebl
Journal:  Internist (Berl)       Date:  2007-07       Impact factor: 0.743

8.  Cognitive behavioural therapy in elderly type 2 diabetes patients with minor depression or mild major depression: study protocol of a randomized controlled trial (MIND-DIA).

Authors:  Frank Petrak; Martin Hautzinger; Kristin Plack; Kai Kronfeld; Christian Ruckes; Stephan Herpertz; Matthias J Müller
Journal:  BMC Geriatr       Date:  2010-05-04       Impact factor: 3.921

9.  Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline.

Authors:  Peter Bramlage; Christiane Binz; Anselm K Gitt; Michael Krekler; Tanja Plate; Evelin Deeg; Diethelm Tschöpe
Journal:  Cardiovasc Diabetol       Date:  2010-09-16       Impact factor: 9.951

10.  Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Authors:  Werner A Scherbaum; Gordon Goodall; Katrina M Erny-Albrecht; Massimo Massi-Benedetti; Erland Erdmann; William J Valentine
Journal:  Cost Eff Resour Alloc       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.